Drugs / VRT106
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06826313 | Mar → Dec 2025 overdue | cancer | Guangzhou Virotech Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06368921 | Jun 2024 → Sep 2026 expected | cancer | Guangzhou Virotech Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07093814 | Sep 2025 → Dec 2028 expected | glioblastoma | Guangzhou Virotech Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06758544 | Mar 2025 → Sep 2026 expected | malignant pancreatic neoplasm | Guangdong Provincial People's Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06866977 | Mar → Oct 2025 overdue | malignant pancreatic neoplasm | Xiangya Hospital of Central South University | Not yet recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07589257 | May 2026 → Jun 2028 expected | diffuse midline glioma, H3 K27M-mutant | Guangzhou Virotech Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07486310 | Mar 2026 → Mar 2028 expected | gastric cancer | Guangdong Provincial People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07589244 | May 2026 → Dec 2028 expected | hepatocellular carcinoma | Guangzhou Virotech Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRT106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06866977 ↗ |
| Route | Other | “intratumoral injection” NCT06368921 ↗ |